Investments, Funding & Disinvestment

Under the deal, Blackstone Life Sciences will provide up to US$800 million in exchange for low- to mid-single-digit tiered royalties on future zumilokibart sales for 15 years.

The facility, which is expected to begin operations in 2027, will become Align Technology’s first manufacturing site in India and its fourth worldwide.

The initiative supports Moscow’s broader oncology modernization strategy, which combines investments in diagnostic technology, artificial intelligence, and clinician education to improve patient outcomes.

The ambitious project targets approximately 1.2 million residents, most of whom inhabit rural communities where traditional connectivity has remained inconsistent.

Health authorities estimate that approximately 20,000 babies are born with the condition each year, while nearly 30 percent of the population carries the sickle cell trait.

The acquisitions of Curevo, LimmaTech Biologics, and Vaccine Company mark the drugmaker’s eighth, ninth, and tenth deals of 2026 as it continues to diversify beyond its blockbuster obesity and diabetes franchises.

The proposed acquisition comes at a time when radiopharmaceuticals are attracting unprecedented attention from investors, healthcare providers, and pharmaceutical manufacturers.

Edge Growth, in partnership with FNB’s Vumela Fund, backed Mia Healthcare at a pivotal stage of its development, reinforcing investor confidence in its business model and growth trajectory.

The deal gives Olympus access to BioProtect’s commercially available implant system designed to protect healthy tissue during radiation therapy.

I-MED operates a network of 215 clinics across Australia and New Zealand and performs more than seven million patient procedures annually.